UNSPSC 51123004: Emilium tosilate

This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) CIQ9QG91PY. European Medicines Agency schedules Emilium tosilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06507MIG. Emilium tosilate generally arises in the molecular formula C12H20NO.C7H7O3S.

The term EMILIUM TOSILATE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 31, no10, 1977, list 17.) Most nations, for tariff and trade purposes, schedule emilium tosilate under HS 29239000 and SITC 51481. SMILES: CC[N+](C)(C)CC1=CC(=CC=C1)OC.CC1=CC=C(C=C1)S(=O)(=O)[O-].

UNSPSC 51123004 Emilium tosilate is a Commodity code that encompasses advanced life support medications and related pharmaceutical products procured by state and local health systems, fire departments, and pharmacy benefit programs. State and local buyers under this code source injectable medications, including vasopressors, cardiac agents, and emergency response drugs required to maintain clinical inventory and meet statutory expiration-date and shelf-life requirements. The issuing bodies include municipal fire rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. Work solicited ranges from direct purchase of specific medication line items with firm pricing and rapid delivery cycles to strategic sourcing of generic pharmaceuticals through manufacturer direct-to-wholesaler distribution networks.

Geographic activity appears concentrated in the South and Upper Midwest, with recent solicitations from the City of Tampa (Florida), the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which coordinates procurement across Minnesota, Oregon, and participating member jurisdictions. The City of Tampa issued an IFB (Bid No. 26P00188) on April 24, 2026, for Advanced Life Support Medications—370 units of Labetalol HCI, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, and 1,020 units of Diltiazem 25mg—with an estimated contract value of $40,000 and a bid deadline of April 8, 2026, under a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. MMCAP issued an RFP (S1070000015802) closing March 26, 2026, to establish multiple manufacturer contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026. The Texas HHS Commission issued an RFI (HHS0017013) in early April 2026 to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions pilot, signaling future formalized procurement as the state develops contracting specifications.